$ERAS news
The latest ERAS stock news: headlines, filings, AI summaries and sentiment for $ERAS, updated around the clock.
- Pomerantz Law Firm Investigates Potential Securities Fraud at Erasca, Inc.
- Erasca, Inc. - 8-K Filing
- Pomerantz Law Firm Announces Class Action Lawsuit Against Erasca, Inc.
- Berger Montague Announces Class Action Against Erasca (NASDAQ: ERAS) Over Alleged Securities Fraud
- Erasca Surges on Positive Phase 1 Trial Results for Cancer Treatment
- Erasca, Inc. - 8-K Filing
- Erasca Prices Upsized $550 Million Public Offering
- Erasca Announces Proposed $500 Million Common Stock Offering
- Erasca, Inc. - 8-K Filing
- Class Action Lawsuit Filed Against Erasca, Inc.
- Erasca Inc. Announces Collaboration with Merck for Clinical Trial
- RTW Investments Makes $189 Million Bet on Erasca Amid Share Price Surge
- Biotech Fund Sells $44.5 Million Stake in Erasca Following a 700% Share Price Rally
- Paradigm Biocapital Sells $44.5 Million Stake in Erasca Following Significant Share Price Increase
- Acuta Capital Acquires Stake in Erasca (ERAS) with $4.19 Million Share Purchase
- Acuta Capital Acquires Stake in Erasca (ERAS) with $4.19 Million Investment
- Hedge Fund Siren Adds $29 Million in Erasca Shares Despite Stock's 700% Surge
- Erasca, Inc. - 10-Q Filing
- Erasca, Inc. - 8-K Filing
- Erasca Announces Positive Preliminary Phase 1 Data for Pan-RAS Molecular Glue ERAS-0015
- Erasca Shares Rise on Positive Cancer Treatment Data
- Erasca Shares Drop 48% After Patient Death in Early Cancer Drug Trial
- Erasca Shares Drop 48% After Patient Death in Early Cancer Drug Trial
- Erasca Reports Negative Phase 1 Trial Data, Shares Drop 37%
- Erasca (ERAS) Reaches 4-Year High Ahead of ERAS-0015 Trial Results